This warrants future studies using mouse models of AD as well as proteomics and transcriptomics-based studies in human patients to examine the pathological vulnerability of specific types of long-range inhibitory projections (regional: MEC vs. LEC; cell-type: SST- vs. PV- vs. VIP-expressing) and their downstream interactions. The gene discussed is VIP; the disease is Alzheimer disease.